scholarly journals Cerebral Venous Thrombosis and COVID-19 Infection in a Patient With Sickle Cell Disease: A Case Report

2021 ◽  
Author(s):  
Athena Sharifi Razavi ◽  
Narges Karimi
Keyword(s):  
Case Report ◽  
Sickle Cell Disease ◽  
Venous Thrombosis ◽  
Sickle Cell ◽  
Cerebral Venous Thrombosis ◽  
Antiviral Agents ◽  
Common Symptom ◽  
Cell Disease ◽  
First Case ◽  
Novel Coronavirus

Background: The most common symptom of the novel Coronavirus Disease 2019 (COVID-19) infection is fever and dyspnea that leads to hypoxia in severe cases. Some COVID-19 patients experience neurological symptoms, including ischemic stroke and intracerebral hemorrhage. Sickle Cell Disease (SCD) is a hypercoagulable state, however, it has not been approved as a significant cause of Cerebral Venous Thrombosis (CVT). Case presentation: In this case report, we described CVT in an SCD patient who had COVID-19, as well. We reported a 32-year-old man with a history of sickle cell anemia presented with left hemiparesis, headache, and seizure. After evaluation of the patient, CVT accompanied by COVID-19 infection was diagnosed. He was treated with intravenous unsaturated heparin, antiepileptic drugs, and antiviral agents with a favorable outcome. Based on our knowledge, this is the first case study to describe an association between CVT and COVID-19 infection in a patient with SCD. Conclusion: During the recent pandemic, vaso-occlusive attacks in SCD patients can be evaluated for COVID-19 as an etiological factor.

scholarly journals Myelopathy in sickle cell disease: a case-oriented review

2021 ◽  
Author(s):  
Igor Vilela Brum ◽  
Guilherme Diogo Silva ◽  
Diego Sant'Ana Sodre ◽  
Felipe Melo Nogueira ◽  
Samira Luisa dos Apostolos Pereira ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Case Report ◽  
Sickle Cell Disease ◽  
Sickle Cell ◽  
Case Reports ◽  
Spinal Cord Infarction ◽  
Sensory Level ◽  
Cell Disease ◽  
Hematopoietic Tissue ◽  
First Case

Background: Although neurological complications are well recognized in sickle cell disease (SCD), myelopathy has been rarely described. We present the first case report of longitudinally extensive myelitis (LETM) in SCD and review the differential diagnosis of myelopathy in these patients. Design and setting: case-oriented review. Methods: We report the case of a 29-year-old African-Brazilian man with SCD, who experienced a subacute flaccid paraparesis, with T2 sensory level and urinary retention. CSF analysis showed a lymphocytic pleocytosis and increased protein levels. MRI disclosed a longitudinally extensive spinal cord lesion, with a high T2/STIR signal extending from C2 to T12. Serum anti-aquaporin-4 antibody was negative. We searched Medline/ PubMed, Embase, Scopus, and Google Scholar databases for myelopathy in SCD patients. Results: Spinal cord compression by vertebral fractures, extramedullary hematopoietic tissue, and Salmonella epidural abscess have been reported in SCD. We found only three case reports of spinal cord infarction, which is unexpectedly infrequent compared to the prevalence of cerebral infarction in SCD. We found only one case report of varicella-zoster myelitis and no previous report of LETM in SCD patients. Conclusion: Specific and time-sensitive causes of myelopathy should be considered in SCD patients. In addition to compression and ischemia, LETM should be considered as a possible mechanism of spinal cord involvement in SCD.

scholarly journals Bordetella Holmesii: An Unusual Cause of Endogenous Endophthalmitis in a Patient With Sickle Cell Disease

2020 ◽  
pp. 247412642094663
Author(s):  
Roma B. Pegany ◽  
Roshan T. George ◽  
Alice Yang Zhang
Keyword(s):  
Visual Acuity ◽  
Case Report ◽  
Sickle Cell Disease ◽  
Sickle Cell ◽  
Acute Onset ◽  
Endogenous Endophthalmitis ◽  
Causative Organism ◽  
Cell Disease ◽  
First Case ◽  
The Right

Purpose: This case report describes a rare organism causing endogenous endophthalmitis in a patient with sickle cell disease. Methods: A case report was conducted. Results: A 41-year-old man with sickle cell disease presented with acute onset of blurry vision of the right eye. His visual acuity was counting fingers in the right eye and 20/20 in the left eye. He had ophthalmic findings of hypopyon and vitritis in the right eye, consistent with endophthalmitis. He was treated with intravitreal and systemic antibiotics. Vitreous cultures grew Bordetella holmesii. His visual acuity at follow-up visits improved to 20/40 in the setting of improved vitritis. Conclusions: This is the first case describing B holmesii, a rare causative organism of endogenous endophthalmitis, in a patient with sickle cell disease. More studies are needed to improve the early detection and treatment of this unusual organism.

scholarly journals Retinopathy Revealing Cerebral Venous Thrombosis in Sickle Cell Disease in Niger

2019 ◽  
Vol 09 (03) ◽  
pp. 134-140
Author(s):  
Nouhou Diori Adam ◽  
Yacoubou Soumana ◽  
Saley Ali ◽  
Amadou Moussa Salia ◽  
Saley Idrissa
Keyword(s):  
Sickle Cell Disease ◽  
Venous Thrombosis ◽  
Sickle Cell ◽  
Cerebral Venous Thrombosis ◽  
Cell Disease

scholarly journals Use of Eculizumab for the Treatment of Hyperhaemolysis in Pregnancy in Sickle Cell Disease: A Case Report

Blood ◽  
2018 ◽  
Vol 132 (Supplement 1) ◽  
pp. 4922-4922
Author(s):  
Laura Chebet Kirui ◽  
Marie Scully ◽  
Norma Mcqueen ◽  
John Porter ◽  
Perla Eleftheriou
Keyword(s):  
Case Report ◽  
Sickle Cell Disease ◽  
Sickle Cell ◽  
Case Reports ◽  
Complex Problem ◽  
Red Cell ◽  
Cell Disease ◽  
Safe Delivery ◽  
First Case ◽  
In Pregnancy

Abstract Hyperhaemolysis is a rare but well recognized complication of transfusion in sickle cell disease, associated with increased mortality. The pathogenesis is not well understood and is likely to be multifactorial. There is no gold standard management of hyperhaemolysis; immunosuppression with steroids and intravenous immuoglobulins has been the mainstay of treatment. More recently Rituximab and Eculizumab are increasingly used. Hyperhaemolysis in pregnancy is an even more complex problem with compounded risk to the mother and foetus. This case reports a 29 year old female with HbSS who presented with hyperhaemolysis in pregnancy at 25 weeks gestation, 7 days after a red cell transfusion for a vaso-occlusive crisis. The patient received 1 g methylprednisolone and 2g/kg immunoglobulins in divided doses. Despite this, she required further blood transfusion as the haemoglobin was declining further and was symptomatic for her anaemia. Her haemoglobin reached a nadir level of 39 g/l. Therefore she was treated with Eculizumab 900 mg iv pre transfusion to prevent exacerbation of the haemolysis triggered by the transfusion. Her haemoglobin stabilised and the haemolysis resolved within 48 hours. She delivered safely at 34 weeks gestation. The DAT remained negative throughout and no new red cell antibodies were detected. Urine HPLC confirmed the presence of HbA and HbS in the urine, confirming the diagnosis. The urine HPLC 48 hr post Eculizumab and 2 further red cell units was clear, demonstrating no further haemolysis with the additional red cells given. This is the first case report detailing the use of Eculizumab for the management of hyperhaemolysis in pregnancy in sickle cell disease. The patient tolerated the treatment which resulted in resolution of the haemolysis, with safe delivery at 34 weeks gestation. The possible role of complement activation in hyperhaemolysis is discussed. The use of Eculizumab in other case reports of hyperhaemolysis is reviewed. The ideal dosing schedule remains uncertain. This report strongly suggests that Eculizumab should be accessible and considered in severe cases of hyperhaemolysis which are refractory to standard treatment. It also suggests safe usage in pregnancy in sickle cell patients. Disclosures Scully: Novartis: Honoraria, Other: Member of Advisory Board, Speakers Bureau. Porter:Cerus: Honoraria; Novartis: Consultancy; Agios: Honoraria.

Lead Neuropathy and Sickle Cell Disease

PEDIATRICS ◽  
1974 ◽  
Vol 54 (4) ◽  
pp. 438-441
Author(s):  
Gerald Erenberg ◽  
Steven S. Rinsler ◽  
Bernard G. Fish
Keyword(s):  
Case Report ◽  
Sickle Cell Disease ◽  
Sickle Cell ◽  
Lead Poisoning ◽  
Cell Disease ◽  
Hemoglobin S ◽  
Increased Risk ◽  
Rare Manifestation ◽  
Poisoning In Children

Four cases of lead neuropathy in children with hemoglobin S-S or S-C disease are reported. Neuropathy is a rare manifestation of lead poisoning in children, and only ten other cases have been well documented in the pediatric literature. The last previous case report of lead neuropathy was also in a child with hemoglobin S-S disease. The neuropathy seen in the children with sickle cell disease was clinically similar to that seen in the previously reported cases in nonsicklers, but differed in both groups from that usually seen in adult cases. It is, therefore, postulated that children with sickle cell disease have an increased risk of developing neuropathy with exposure to lead. The exact mechanism for this association remains unknown, but in children with sickle cell disease presenting with symptoms or signs of peripheral weakness, the possibility of lead poisoning must be considered.

scholarly journals Spontaneous subgaleal hematoma in a patient with sickle cell disease: A case report and literature review

2019 ◽  
Vol 7 (11) ◽  
pp. 2220-2224
Author(s):  
Mohammed S. Foula ◽  
Ali Hassan ◽  
Ahmed AlQurashi ◽  
Amna Alsaihati ◽  
Mohammed Sharroufna
Keyword(s):  
Case Report ◽  
Sickle Cell Disease ◽  
Literature Review ◽  
Sickle Cell ◽  
Cell Disease ◽  
Subgaleal Hematoma
Sign in / Sign up

Export Citation Format

Share Document